Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 191

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 191
---
 2025. In October 2024, or the October 2024 Addendum, we proposed to the lenders under the 2020 CLAs
to increase principal amount under their respective portion of the 2020 CLA, up to an additional aggregate amount of $450,000, so that
the 2020 CLAs shall bear interest at 8% per annum until maturity commencing as of July 1, 2024 with respect to non-participating lenders
and March 31, 2025 with respect to participating lenders. In addition, pursuant to the October 2024 Addendum, we agreed to pay the participating
lenders at maturity an additional aggregate amount of 340,000 as a risk premium, and upon the occurrence of an initial public offering
based on a pre money valuation of $5.15 million, the 2020 CLAs shall be automatically converted into 609,888 Ordinary Shares and the
Additional Amount in addition to the risk premium and the Interest Amount (each as defined therein) shall be automatically converted
into 553,640 Ordinary Shares.

Other Financings

Between October 2024 and November 2024, we entered into bridge loan
agreements, or the Bridge Loans, pursuant to which we obtained a bridge loan in the total amount of $350,000 from certain lenders (out
of which, an amount of $100,000 was received subsequent to December 31, 2024), including Dr. Ehud Geller, the chairman and a member of
our board of directors, and Pini Ben Elazar, a director nominee. The Bridge Loans shall bear interest at 8% per annum until maturity and
we agreed to pay the lenders an additional risk premium equal to 30% of their respective loan amount. In October 2024, we amended the
Bridge Loans pursuant to which the Bridge Loans may be extended beyond March 31, 2025 and until June 30, 2025, subject to the Registration
Statement effectiveness not later than March 31, 2025 and the fulfillment of additional cumulative conditions. Furthermore, upon the occurrence
of an initial public offering of our securities for a total offering of
not less than $6,000,000 (a “Qualified IPO”), the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times
their respective loan amount in addition to the risk premium based on a price per share equal to 75% of the